IDEXX Laboratories Inc
NASDAQ:IDXX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
IDEXX Laboratories Inc
Net Issuance of Debt
IDEXX Laboratories Inc
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
Net Issuance of Debt
-$30.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Net Issuance of Debt
-$491m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Net Issuance of Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Stryker Corp
NYSE:SYK
|
Net Issuance of Debt
$1.6B
|
CAGR 3-Years
50%
|
CAGR 5-Years
10%
|
CAGR 10-Years
42%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Net Issuance of Debt
-$1.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-83%
|
CAGR 10-Years
-14%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Net Issuance of Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
IDEXX Laboratories Inc
Glance View
IDEXX Laboratories Inc. stands as a pillar of innovation in the realm of veterinary diagnostics, transforming the landscape of animal healthcare. Founded in 1983, the company has strategically positioned itself at the intersection of science and care, delivering a broad range of products and services that cater primarily to veterinarians. By offering state-of-the-art diagnostic tests and in-house laboratory equipment, IDEXX empowers veterinarians to make precise and timely decisions. These tools not only enhance animal health but also streamline veterinary practices, allowing them to offer clients rapid, reliable results. By investing heavily in research and development, IDEXX continuously enhances its product portfolio, maintaining a competitive edge in a market that demands constant innovation. In addition to its core veterinary diagnostic services, IDEXX extends its expertise into water testing and livestock and poultry diagnostics, though these segments are smaller. The company crafts its revenue model on providing recurring, subscription-based services for its diagnostic machines, which require regular updating with new test kits and consumables. This model ensures a durable revenue stream, fostering long-term relationships with veterinary clinics worldwide. As digital transformation sweeps through every industry, IDEXX has also embraced the digital age, crafting sophisticated software that aids veterinarians in managing their practices more efficiently, thus augmenting its revenue through IT solutions. This diversified yet synergistic approach has allowed IDEXX to remain resilient and grow steadily, delivering consistent value to both its clients and shareholders.
See Also
What is IDEXX Laboratories Inc's Net Issuance of Debt?
Net Issuance of Debt
-30.4m
USD
Based on the financial report for Dec 31, 2025, IDEXX Laboratories Inc's Net Issuance of Debt amounts to -30.4m USD.
What is IDEXX Laboratories Inc's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 5Y
19%
Over the last year, the Net Issuance of Debt growth was 59%.